Healthcare / Medical DevicesWarsaw
$271.20
+0.20 (+0.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 27% · confianza 25%
FCF escenarios
weak_data · normalized FCF $60.9M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
17.4x
↓EV/EBITDA
12.6x
↑ROE
46.0%
↑Gross Margin
35.7%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+59.9%
FCF CAGR
—
FCF margin
8.9%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $681.6M · net income $102.9M · FCF $60.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $681.6M | $681.6M | $624.1M | $446.9M | $166.9M |
| Net Income | $102.9M | $102.9M | $82.6M | $52.5M | $10.3M |
| EBITDA | $179.6M | $179.6M | $141.8M | $82.4M | $25.8M |
| EPS | 12.07 | 12.07 | 9.68 | 6.15 | 1.21 |
| Gross Margin | 35.7% | 35.7% | 30.4% | 29.5% | 29.1% |
| Operating Margin | 23.5% | 23.5% | 20.6% | 15.8% | 6.8% |
| Net Margin | 15.1% | 15.1% | 13.2% | 11.7% | 6.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.13 | 0.14 | 0.42 |
| Current Ratio | 1.07 | 1.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $60.9M | $60.9M | $44.7M | $86.4M | $-16.4M |
| Returns | |||||
| ROE | 46.0% | 46.0% | 43.5% | 39.1% | 11.7% |
| Valuation | |||||
| P/E | 17.43 | 17.43 | 18.80 | 9.43 | 25.45 |
| EV/EBITDA | 12.64 | 12.64 | 10.52 | 5.47 | 11.24 |
| P/B | 10.35 | 10.35 | 8.17 | 3.69 | 2.99 |
| Growth & Yield | |||||
| Revenue Growth | 9.2% | 9.2% | 39.7% | 167.8% | — |
| EPS Growth | 24.7% | 24.7% | 57.4% | 408.3% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
25.9%
EPS terminal req.
$24.06
Spread vs growth
-1.2%
5Y implied EPS CAGR
19.3%
EPS terminal req.
$29.12
Spread vs growth
5.4%
10Y implied EPS CAGR
14.5%
EPS terminal req.
$46.89
Spread vs growth
10.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.2%
Start / end P/E
22.7x → 22.5x
EPS bridge
9.68 → 12.07
Residual
-0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.